Renaissance Capital logo

Marinus Pharmaceuticals Priced, Nasdaq: MRNS

Early-stage biotech developing an add-on therapy for epilepsy.

Industry: Health Care

First Day Return: 0.0%

Industry: Health Care

Early-stage biotech developing an add-on therapy for epilepsy.
more less

Marinus Pharmaceuticals (MRNS) Performance